Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046128 | 0.88 | KDM4E (0.36) | ALDH1A1KDM4ELMNANAMPT | |
| SCHEMBL4044854 | 0.87 | FKBP1A (0.37) | NAMPT | |
| SCHEMBL4046518 | 0.85 | ESR1 (0.31) | — | |
| SCHEMBL4040334 | 0.83 | TBXAS1 (0.36) | ALDH1A1DPP4PREPFAPDPP8 | |
| SCHEMBL4040282 | 0.83 | PIK3CD (0.35) | ALDH1A1DPP4PREPFAPDPP8 | |
| SCHEMBL4043173 | 0.81 | MAPK1 (0.33) | ALDH1A1MAPTDPP4PREPFAP | |
| SCHEMBL4043899 | 0.81 | PAX8 (0.36) | ALDH1A1MAPTOPRM1OPRK1 | |
| SCHEMBL4043695 | 0.81 | ELOVL6 (0.35) | — | |
| SCHEMBL4041690 | 0.81 | KMT2A (0.32) | KMT2ADPP4PREPFAPDPP8 | |
| SCHEMBL6240091 | 0.81 | PREP (0.37) | ALDH1A1DPP4PREPFAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | KMT2A 3867/4885ALDH1A1 4151/4885KDM4E 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.